Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Monopar Therapeutics Director's Dealing 2025

Mar 5, 2025

32883_dirs_2025-03-05_953b6857-1b96-4a88-9920-486b5cbff8df.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-03-03

Reporting Person: Vu Quan Anh (Chief Financial Officer)

More from Monopar Therapeutics

Regulatory Filings 2026
May 29
Regulatory Filings 2026
May 19
Interim / Quarterly Report 2026
May 14
Regulatory Filings 2026
May 14
Annual Report 2026
Apr 30
Regulatory Filings 2026
Apr 20
Annual Report 2026
Apr 1
Annual Report 2026
Mar 27
Director's Dealing 2026
Mar 4
Regulatory Filings 2026
Mar 2
View all filings →